A narrative review of stem cell-based therapy for fibrosing interstitial lung diseases: clinical evidence and translational perspectives
- 1Research and Development Center, Tianjin Huayu Pharmaceutical Co., Ltd.
Abstract
Fibrosing interstitial lung diseases (F-ILD) are a heterogeneous group of disorders characterized by pulmonary interstitial fibrosis and inflammation. Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of F-ILD. Regulator-approved anti-fibrotic drugs, such as pirfenidone and nintedanib, delay rather than reverse disease progression, so the threat of eventual respiratory failure remains. While lung transplantation is an option that can prolong survival for end-stage IPF, its clinical application is greatly restricted by donor shortages, surgical risks, and postoperative complications. Stem cell therapies, and particularly treatments based on mesenchymal stromal/stem cells (MSCs) and their derivatives, have brought new hope for the management of F-ILD due to their immune regulatory, anti-inflammatory, and anti-fibrotic capabilities. A search was conducted to identify relevant articles in the PubMed/MEDLINE, Web of Science, Cochrane Library, China National Knowledge Internet and Wanfang Data from inception to 31st May 2026. This review summarizes the mechanistic overview of stem cell-based therapeutic strategies for F-ILD, safety profiles and therapeutic potentials of various stem cells for the treatment of IPF and other F-ILDs, with an emphasis on stem cell types and delivery routine. This article also discusses the challenges and limitations of stem cell-based therapies, highlighting the need for further clinical studies with standardized efficacy endpoints to validate their effectiveness.
Related
- Low-energy extracorporeal shock wave therapy for interstitial cystitis/bladder pain syndrome: mechanisms, evidence, and translational perspectives—a narrative review
- Health-Related Quality of Life in Patients With Fibrosing Interstitial Lung Diseases: A Study Using the King’s Brief Interstitial Lung Disease (K-BILD) Questionnaire
- MMP-7 as a non-invasive biomarker in interstitial lung diseases and other chronic respiratory diseases: a narrative review
- Cellular immunotherapy for lung cancer: current clinical evidence, translational challenges, and future perspectives: a narrative review
- Endoplasmic reticulum stress and maladaptive repair in fibrotic interstitial lung diseases: A human-evidence-based narrative review
BibTeX
@article{li2026narrative,
title = {{A narrative review of stem cell-based therapy for fibrosing interstitial lung diseases: clinical evidence and translational perspectives}},
author = {Zhengnan Li and Lei Geng and Wei Li and Xiujuan Wang and Xiu’e Wang and Zhen Qin and Ya'nan Zhang and Chunlin Mou},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1917005},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1917005/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A narrative review of stem cell-based therapy for fibrosing interstitial lung diseases: clinical evidence and translational perspectives
AU - Zhengnan Li
AU - Lei Geng
AU - Wei Li
AU - Xiujuan Wang
AU - Xiu’e Wang
AU - Zhen Qin
AU - Ya'nan Zhang
AU - Chunlin Mou
PY - 2026
DA - 2026/10/07
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1917005
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1917005/full
AB - Fibrosing interstitial lung diseases (F-ILD) are a heterogeneous group of disorders characterized by pulmonary interstitial fibrosis and inflammation. Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of F-ILD. Regulator-approved anti-fibrotic drugs, such as pirfenidone and nintedanib, delay rather than reverse disease progression, so the threat of eventual respiratory failure remains. While lung transplantation is an option that can prolong survival for end-stage IPF, its clinical application is greatly restricted by donor shortages, surgical risks, and postoperative complications. Stem cell therapies, and particularly treatments based on mesenchymal stromal/stem cells (MSCs) and their derivatives, have brought new hope for the management of F-ILD due to their immune regulatory, anti-inflammatory, and anti-fibrotic capabilities. A search was conducted to identify relevant articles in the PubMed/MEDLINE, Web of Science, Cochrane Library, China National Knowledge Internet and Wanfang Data from inception to 31st May 2026. This review summarizes the mechanistic overview of stem cell-based therapeutic strategies for F-ILD, safety profiles and therapeutic potentials of various stem cells for the treatment of IPF and other F-ILDs, with an emphasis on stem cell types and delivery routine. This article also discusses the challenges and limitations of stem cell-based therapies, highlighting the need for further clinical studies with standardized efficacy endpoints to validate their effectiveness.
SN - 1663-9812
ER -